RE: RNS18 Dec 2018 07:21
Results publication
The peer-reviewed article will appear in the European Journal of Drug Metabolism and Pharmacokinetics early in 2019. The article details and analyses the pharmacokinetic data acquired during the VAL401, Phase II clinical trial that was concluded in Tbilisi, Georgia in 2017. VAL401 is a new formulation of the anti-psychotic drug, risperidone, enabling our oncology treatment. This analysis considers the clinical significance of the VAL401 results in comparison to previously reported data for conventional risperidone, providing a theoretical insight into the altered activity of the therapeutic.